<DOC>
	<DOC>NCT01745848</DOC>
	<brief_summary>Our primary hypothesis is that Roflumilast (500 Î¼cg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.</brief_summary>
	<brief_title>Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Subjects between the ages of 50 and 70 with a minimum of tenpack years of tobacco exposure, airflow obstruction (FEV1/FVC &lt; 0.70) with an FEV1 &lt; 70% baseline sputum production at least some of the time as reported on the Saint George's Respiratory Questionnaire, and at least one exacerbation within the past year Subjects with chronic prednisone use, antiresorptive therapy use (bisphosphonates, calcitonin, parathyroid hormone) Subjects with a body mass index less than 18 or greater than 34</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Roflumilast</keyword>
	<keyword>COPD</keyword>
</DOC>